Rocket Pharmaceuticals Watchlist

tz-plus logo Rocket Pharmaceuticals: How Danon Studies Drive Valuation Levels - Experts See Up to 422% Price Potential!

M. Herzberger
Reading Time: 3 minutes

Focus on AAV-based gene therapies for rare diseases, with Danon disease as the primary pipeline driver. Wedbush analyst Yun Zhong sees a price potential of 421.74%, despite a slight reduction in the price target. Cash reserves of $279.4 million secure financing for clinical trials through the third quarter of 2028. Focus on AAV vectors for rare hereditary diseases Rocket Pharmaceuticals (RCKT) is focused on developing gene therapies for serious pediatric diseases. The business model is based on the use of adeno-associated virus vectors...

Read this article now with a free account.

Your benefits:

  • Every month, you can read 5 articles from the premium section for free.
  • Monthly 2 trial issues of the Trader newspaper for free.
  • Create a personal watchlist with an overview of news about your stock.
Trader Times
Free account
Here we go!
Image 1Image 2Image 3

Already registered? Log In